|Bid||5.35 x 2200|
|Ask||5.76 x 29200|
|Day's range||5.49 - 5.70|
|52-week range||3.38 - 10.88|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||N/A|
|Earnings date||30 Jul 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.93|
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 16.67% and -10.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
WALTHAM, Mass., July 30, 2021--ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results